Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM

Plain-language summary

This study examines how gene polymorphisms relate to susceptibility to type 2 diabetes and to the response to the GLP-1 receptor agonist Exenatide in Chinese patients with type 2 diabetes. It enrolls patients aged 25-70 with a diagnosis of type 2 diabetes and a body mass index of 20-35 kg/m2. The study does not use a phase designation and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Recruiting

Sponsor

The Affiliated Hospital of Xuzhou Medical University

Intervention

GLP-1 receptor agonist, responders group and nonresponders group

Start date

1/1/2024

Estimated completion

1/31/2028

Countries

China

Related genes

Locations

• Xuzhou, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. a diagnosis of T2DM
2. a body mass index (BMI) of 20-35 kg/m2
3. an HbA1c of 7.0%-12%, an age of 25-70 years
4. required data available at baseline and 6 months after GLP-1RA therapy.

Exclusion Criteria:

1. Patients with serious diseases such as acute myocardial infarction, cerebral vascular accident, trauma, kidney or liver diseases, severe gastrointestinal dysfunction, and history of pancreatitis
2. patients receiving GLP-1 analogues, weight loss drugs, glucocorticoids, drugs affecting gastrointestinal peristalsis in the past 3 months
3. those with missing data at the time points of baseline, 3 months, and 6 months after GLP-1 RA therapy.